Telaprevir for the treatment of chronic hepatitis C infection

A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis C

(2011) Lisa I. Backus et al.   Clinical Gastroenterology and Hepatology

Inosine Triphosphate Protects Against Ribavirin-Induced Adenosine Triphosphate Loss by Adenylosuccinate Synthase Function

(2011) Yuki Hitomi et al.   GASTROENTEROLOGY

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

(2011) Varun Garg et al.   HEPATOLOGY

1369 TELAPREVIR SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL

(2011) I.M. Jacobson et al.   JOURNAL OF HEPATOLOGY

1356 QUADRUPLE THERAPY WITH BMS-790052, BMS-650032 AND PEG-IFN/RBV FOR 24 WEEKS RESULTS IN 100% SVR12 IN HCV GENOTYPE 1 NULL RESPONDERS

(2011) A. Lok et al.   JOURNAL OF HEPATOLOGY

8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS

(2011) J.C. Sullivan et al.   JOURNAL OF HEPATOLOGY

IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C

(2011) Kazuaki Chayama et al.   JOURNAL OF INFECTIOUS DISEASES

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

(2011) Kenneth E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy

(2010) C. M. Lange et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus

(2010) Alexander J. Thompson et al.   GASTROENTEROLOGY

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir

(2010) Fumitaka Suzuki et al.   HEPATOLOGY

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

(2010) Jacques Fellay et al.   NATURE

Telaprevir for Previously Treated Chronic HCV Infection

(2010) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes

(2009) Y. Rotman et al.   JOURNAL OF VIROLOGY

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

(2008) Eric Lawitz et al.   JOURNAL OF HEPATOLOGY